ESR1 and neoplasm: Several mechanisms of de novo and acquired endocrine therapy resistance have been described, including loss of ER expression, ER crosstalk with growth factor receptors, subclonal genomic alterations of tumor suppressors or drivers, and acquisition of ESR1 fusions or activating ESR1 missense mutations [23, 39, 40].